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OBJECTIVE—TodeterminetherelationshipbetweenselectedcytokinesanddiabetesinChinese
subjects.
RESEARCH DESIGN AND METHODS—Adult patients with recent-onset type 1 diabe-
tes(n=53),latentautoimmunediabetesinadults(LADA)(n=250),andtype2diabetes(n=285)
from multiple centers were compared with normal subjects (n = 196). We centrally tested serum
GAD antibodies (GADAs), interleukin-6 (IL-6), lipocalin 2 (LCN2), high-sensitivity C-reactive
protein (hs-CRP), and adiponectin.
RESULTS—After adjustment for age, sex, and BMI, all diabetes types had increased IL-6 and
LCN2 (P , 0.01), and all four cytokines were increased in LADA (P , 0.01). In type 1 diabetes,
adiponectinbutnoths-CRPwasincreased(P,0.01),whereasintype2diabetes,hs-CRPbutnot
adiponectin was increased (P , 0.01). Adiponectin was correlated positively with GADA titer
and negatively with hs-CRP (P , 0.01 for both).
CONCLUSIONS—In China, inﬂammatory markers are increased in all three major types of
diabetes, but probably for different reasons, even in autoimmune diabetes.
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A
ltered inﬂammatory mediators in
diabetes could either reﬂect the
cause of the disease or be secondary
to metabolic derangements associated
with diabetes. In type 2 diabetes, some
cytokines (interleukin-6 [IL-6] and lipo-
calin 2 [LCN2]) are associated with in-
sulin resistance (1) and others, such as
serum high-sensitivity C-reactive protein
(hs-CRP) and adiponectin, with cardio-
vascular risk (2,3). If these altered cyto-
kines are secondary to the disease, then
weshouldﬁndthemindiabetes,irrespec-
tive of type. If they are involved speciﬁ-
cally in that disease process, then a
speciﬁcp r o ﬁle of altered cytokine levels
might be found in a particular type of di-
abetes. We hypothesized that a diabetes
type–speciﬁcc y t o k i n ep r o ﬁle would be
associated with autoimmune diabetes
and,therefore,foundinlatentautoimmune
diabetes in adults (LADA) and type 1
diabetes.
RESEARCH DESIGN AND
METHODS—We studied cross-
sectionally clinic- and hospital-based
adult diabetic patients (aged .30 years)
within 1 year from diagnosis. We ascer-
tained subjects with LADA and type 2
diabetes from the LADA China multi-
center study (46 hospitals throughout
China contributed); type 1 diabetes, de-
ﬁnedbyWHOcriteria(4),fromtheType1
DiabetesCollaborationNet(18hospitalsin
HunanProvince);andnormalsubjectswere
screened by 75-g oral glucose tolerance
test from 5,000 Chinese in a population-
based study. Deﬁnition of LADA (5–7)
was 1) GAD antibody (GADA) positive,
2)a g e.30 years at diagnosis, 3) indepen-
dence from insulin treatment 6 months
postdiagnosis, and 4) without ketoacidosis.
Type 2 diabetic patients were GADA nega-
tive and noninsulintreated 6 months post-
diagnosis.Subjectswithhs-CRP.10mg/L
ortakinganti-inﬂammatorydrugswithin
3 months were excluded. Metabolic
syndrome was deﬁned by National Cho-
lesterol Education Program-Adult Treat-
mentPanelIIIcriteria(8).Thisstudywas
approved by ethics committees at Second
Xiangya Hospital of Central South Univer-
sity and at each center and conducted
according to the Declaration of Helsinki.
All participants provided written informed
consent.
Height, weight, waist circumference,
hip circumference, and blood pressure
were recorded locally, and fasting sera
samples were processed centrally. GADA
was measured by radioligand assay (9).
ELISA determined high-sensitivity IL-6
(IL-6 HS; R&D Systems, Minneapolis,
MN),7%intraassayand5%interassayco-
efﬁcient of variation (CV); LCN2 (10),
3.8–6.0% intraassay and 3.1–5.2% inter-
assay CV; adiponectin (11) 5–6% intra-
assay and 6–8% interassay CV. Hs-CRP
was measured by immunoturbidometric
assay (Orine Diagnostica) with 2.1–3.3%
intraassay and 3.4–4.6% interassay CV.
Statistical analysis
We used SPSS (version 13; SPSS, Chicago,
IL) for statistical analysis. Data are ex-
pressed when normally distributed as
means 6 SD and when skewed as median
(25th–75th percentiles). Logarithmic
transformations were applied on non–
normally distributed parameters before
comparison. Frequency differences were
compared using x
2 test. Variance analysis
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BRIEF REPORTcompared means by one-way ANOVA as
appropriate. We used a general linear
model of univariate analysis adjusted for
age, sex, and BMI; log-transformed cyto-
kinevaluewasthedependentvariable,dif-
ferentdiabetesgroupswereﬁxed,andage,
sex,andBMIwerecovariates(Fig.1).Mul-
tivariate regression models investigated
differences in log-transformed cytokine
concentrations (dependent variables), with
increasing number of variables (model 1:
unadjusted; model 2: sex and age
adjusted; model 3: age, sex, and BMI [in-
dependent variables] adjusted) (Supple-
mentary Table 2). Linear relationships
were evaluated by partial correlations test
adjusted age, sex, and BMI. Data were not
corrected for multiple comparisons and
are descriptive; P , 0.01 was considered
signiﬁcant.
RESULTS—Results are shown in Sup-
plementary Table 1. Of 784 subjects, pa-
tientswithbothLADAandtype2diabetes
weresigniﬁcantlyolderthansubjectswith
normalglucosetoleranceortype1diabetic
patients. As expected, LADA patients had
lower insulin secretion than type 2 dia-
betic patients, while in type 1 diabetic pa-
tients, insulin secretion was lower than in
both LADA and type 2 diabetic patients.
Metabolicsyndromeintype1diabeticand
control subjects was less frequent than in
both LADA and type 2 diabetic subjects.
We used univariate and multivariate re-
gression models to adjust age, sex, and
BMI differences (Fig. 1 and Supplemen-
tary Table 2). After adjustment, all three
types of diabetes (type 1 diabetes, LADA,
andtype2diabetes)showedincreasedIL-6
and LCN2. All four cytokines were
increased in LADA. In type 1 diabetes,
adiponectin but not hs-CRP was in-
creased. In type 2 diabetes, hs-CRP but
not adiponectin was increased, and adi-
ponectin was decreased after adjustment.
GADA titer was positively correlated
with adiponectin (r = 0.14, P , 0.01)
and negatively correlated with hs-CRP
(r = 20.15, P , 0.001) (Supplemen-
tary Tables 3 and 4). In LADA subjects,
hs-CRP was strongly related to BMI (r =
0.363, P , 0.001).
CONCLUSIONS—Some inﬂammatory
markerswereincreasedindiabetes(i.e.,IL-6
and LCN2) irrespective of diabetes type,
implying that cytokine changes are sec-
ondary features of the disease indepen-
dent of obesity, and consistent with a
proinﬂammatory effect in diabetes in gen-
eral. Nevertheless, obesity (waist-to-hip ra-
tio) was associated with all four cytokines
assayed,andthepatternofcytokinechanges
differed according to diabetes type.
Cytokines (IL-6, TNFa, and IL-1 re-
ceptor antagonist) in Europeans with
these same major diabetes types were
also positively associated with BMI,
which was higher in diabetic patients
than in control subjects and highest in
type 2 diabetes but similar in LADA and
type 1 diabetes; after correction, only
TNFa in LADA and type 1 diabetes was
no longer different from that in control
subjects (5). In both the European study
and this Chinese study, IL-6 showed re-
markably similar increases in major dia-
betes types; IL-6, as well as LCN2, levels
were higher than in control subjects and
highest in type 2 diabetes (5). However,
hs-CRP was increased in both LADA and
type 2 diabetes, but not type 1 diabetes,
while adiponectin was only increased in
LADAand type1diabetes.Despite adipo-
nectin being positively correlated with
GADA titer, it has no established role in
autoimmune diabetes and certainly can-
not predict it (12). However, low-grade
inﬂammationcouldbeimportantinauto-
immunity, potentially explaining any
beneﬁt of rosiglitazone (13). Indeed,
each cytokine (IL-6, LCN2, hs-CRP, and
adiponectin) was increased in Chinese
LADA, though probably for different rea-
sons (14). Given the relative lack of obe-
sity in China, comparative Chinese and
European studies could delineate the re-
lative roles of obesity, diabetes, and auto-
immunity on cytokines. Surprisingly,
therefore, metabolic syndrome was preva-
lentinthislargeLADAcohort,incontrastto
European studies (5,6). These results point
toward a complex relationship between
diabetestypesandalteredcytokinelevels.
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Figure 1—Cytokine levels in subtypes of diabetes and normal subjects. Univariate of general
linear model adjusted according to age, sex, and BMI between groups. *P , 0.05, **P , 0.01,
***P,0.001.NGT,normalglucosetolerancesubjects;T1D,type1diabeticsubjects;T2D,type2
diabetic subjects.
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